Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.32 |
| ▸ | PPARG | P37231 | 6/20 | 0.32 |
| ▸ | PPARD | Q03181 | 6/20 | 0.32 |
| ▸ | PPARA | Q07869 | 6/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.32 |
| ▸ | TSHR | P16473 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | FABP4 | P15090 | 2/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL4292824 | 1.00 | MEN1 (0.35) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL9274885 | 0.97 | CES2 (0.36) | MEN1KMT2ACES2GGPS1GPR84 | |
| SCHEMBL5178373 | 0.94 | CES2 (0.38) | MEN1KMT2ACES2GGPS1GPR84 | |
| SCHEMBL5179328 | 0.92 | CES2 (0.39) | MEN1KMT2ACES2GGPS1GPR84 | |
| SCHEMBL5665231 | 0.92 | CES2 (0.39) | MEN1KMT2ACES2GGPS1GPR84 | |
| SCHEMBL4057603 | 0.92 | CES2 (0.39) | MEN1KMT2ACES2GGPS1GPR84 | |
| SCHEMBL5983660 | 0.92 | CES2 (0.39) | MEN1KMT2ACES2GGPS1GPR84 | |
| SCHEMBL2682265 | 0.92 | CES2 (0.39) | MEN1KMT2ACES2GGPS1GPR84 | |
| Acetic Acid SCHEMBL1334243 | 0.88 | HSPD1 (0.38) | MEN1KMT2AMAPTGPR84PPARD | |
| SCHEMBL5795602 | 0.88 | CES2 (0.34) | MEN1KMT2ACES2GGPS1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179932-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| EP-0590022-A1 | IMIDAZO 1,5-a]QUINOXALINES | PHARMACIA & UPJOHN COMPANY (US) | 1994-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179932-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | ESR1 3907/4885MEN1 4333/4885KMT2A 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.